5-fluorocytosine

Inside susceptible fungal cells, cytosine deaminase converts 5-fluorocytosine to 5-fluorouracil. This activation is central to its selective action because the drug must first be transformed before its biologically disruptive metabolites are produced. The intracellular conversion links drug entry with the later effects on fungal nucleic-acid and protein production.

The metabolites generated from 5-fluorouracil disrupt DNA synthesis and impair RNA and protein production. These effects interfere with several processes needed for fungal cell function rather than acting through a single downstream target described in the overview. Consequently, successful activation inside the cell can impair fungal growth and support clearance of infection.

Combining 5-fluorocytosine with amphotericin B pairs two antifungal approaches with complementary mechanisms. The combination is commonly used for serious infections such as cryptococcal meningitis, where complementary activity can improve fungal clearance. This strategy does not remove the need for monitoring, because resistance and toxicity remain important concerns during treatment.

Resistance to 5-fluorocytosine may develop rapidly, so an initially useful regimen can lose effectiveness during treatment. This concern reinforces the need for pharmacological supervision and attention to whether treatment remains appropriate. In serious infections, clinicians commonly combine it with amphotericin B, whose complementary activity can improve fungal clearance, but resistance remains a distinct problem.

The oral option is particularly relevant when clinicians are treating serious fungal infections caused by susceptible yeasts. In the overview’s example, 5-fluorocytosine is used in the context of cryptococcal meningitis, commonly alongside amphotericin B. Its value therefore lies not only in antifungal activity, but also in providing an oral component within treatment of a severe infection.

Pharmacological supervision focuses on potential reductions in blood cell counts and liver toxicity. These adverse effects make clinical follow-up important while treatment is underway, especially for immunocompromised patients with serious fungal infections. Monitoring is therefore part of responsible use rather than an optional addition, allowing clinicians to account for treatment-related safety concerns alongside the need for fungal clearance.